4D Molecular Therapeutics is a clinical-stage biotherapeutics company specializing in targeted genetic medicines through the innovative application of directed evolution. Utilizing their Therapeutic Vector Evolution (TVE) platform, 4DMT aims to unlock the full potential of gene therapy by creating evolved adeno-associated virus (AAV) vectors designed for improved therapeutic efficacy. The company has an extensive pipeline that includes five product candidates in clinical trials targeting major diseases such as wet age-related macular degeneration and cystic fibrosis, along with two preclinical programs. Committed to addressing broader health challenges, 4DMT employs a fully integrated approach with internal capabilities for research, manufacturing, and regulatory compliance. Their mission centers on transforming the lives of patients by developing genetic medicines that can treat a wide array of diseases, expanding beyond the traditional focus on rare conditions.